42 results about "Anaphylactic shock" patented technology

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

The present invention discloses the method of inhibiting complement activation mediated by factor B inhibitors, that involves: (a) inhibiting factor B binding to properdin-bound C3b; (b) inhibiting the release of Bb; (c) inhibiting the activation of neutrophils, monocytes, platelets, and endothelium; or (d) inhibiting / reducing the formation of PC3bBb, C3a, C5a, and MAC. The present invention also discloses the novel use of factor B inhibitors in the treatment of various immunological disorders, resulting either primarily from direct immune responses such as rheumatoid arthritis, anaphylactic shock, myasthenia gravis, asthma, Alzheimer's disease, and the like, or secondarily from clinical conditions such as cardiopulmonary bypass inflammation, vascular stenosis and restenosis, burn injury, and the like.

Systems and methods for prediction and detection of circulatory shock using estimates or measurements of arterial blood pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, cardiac ejection fraction, cardiac contractility and ventricular end-diastolic volume are provided. These estimates and measurements are used to determine a type of circulatory shock. In some embodiments, the type of circulatory shock is determined to be one of septic shock, hypovolemic shock, anaphylactic shock, hemorrhagic shock, and cardiogenic shock.

The present invention includes methods and devices for treating hypotension, such as in cases of shock, including septic shock, anaphylactic shock and hypovolemia. The method includes the step of applying at least one electrical impulse to at least one selected region of a parasympathetic nervous system of the patient. The electrical impulse is sufficient to modulate one or more nerves of the parasympathetic nervous system to increase the ratio of blood pressure to heart rate and relieve the condition and / or extend the patient's life.

Methods and devices for treating hypotension, such as in cases of shock, including septic shock and anaphylactic shock, wherein the treatment includes providing an electrical impulse to a selected region of the vagus nerve of a patient suffering from hypotension to block and / or modulate nerve signals that regulate blood pressure.

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

The present invention relates to novel biologically active glutarimide derivatives of general formula (I) or a pharmaceutically acceptable salt thereof, their use as a therapeutic agent for the treatment of eosinophilic diseases, preferably of allergic nature, in particular bronchial asthma, allergic rhinitis, polypous rhinosinusopathies, eosinophilic colitis, eosinophilic syndrome, allergic conjunctivitis, atopic dermatitis, Churg-Strauss syndrome, anaphylactic shock, Quincke's edema, eosinophilic vasculitis, eosinophylic esophagitis, eosinophilic gastroenteritis, or fibroses. The invention also relates to pharmaceutical compositions comprising glutarimide derivatives of general formula (I):

The invention discloses a traditional Chinese medicine preparation method for the treatment of deficiency of vital energy and fever of children, belonging to the technical field of traditional Chinese medicine preparation methods. If penicillin is used, an allergic reaction is liable to occur, in particular the anaphylactic shock which can jeopardize life without timely rescue. The inventive technical proposal are that: 20 drugs of milk veteh, codonopsis pilosula, atractylodes macrocephala, caryophyllaceous ginseng, yam, jujube, sealwort, maltose syrup, cotton root, bidens tripartite, Chinese thorowax, cimicifuga foetida, root of kudzu vine, fructus viticis, periostracum cicadae, Chinese tamarisk, light black bean, burdock, pericarpium citri reticulatae and licorice are put into 1000 milliliters of water for being immersed for 30 minutes and then decocted with soft fire, the decocted medicine liquid is filtered and deslagged to decoct 180 milliliters of the medicine liquid, which is the traditional Chinese medicine for the treatment of deficiency of vital energy and fever of children. The invention has the advantages that: the Chinese medicine liquid is simple in preparing, less in Chinese medicine toxic side effect, easy in absorption, short in courses of the treatment and high in cure rate as well as can avoid bad reactions caused by the application of the penicillin.

Methods and devices for treating hypotension, such as in cases of shock, including septic shock and anaphylactic shock, wherein the treatment includes providing an electrical impulse to a selected region of the vagus nerve of a patient suffering from hypotension to block and / or modulate nerve signals that regulate blood pressure.

Medical devices and methods for rapid and efficient systemic drug delivery via mucous membranes, particularly oral mucosae, are described. Use of such devices and methods are particularly easy for people without any medical training to employ should they be called upon to provide emergency medical treatment for a victim suffering from anaphylactic shock, opioid overdose, or other life-threatening events. In some embodiments, the device includes an applicator tip with a porous application layer positioned on the end of an elongate handle. The device may also include various means for disrupting a barrier to facilitate mixing of compounds, including an active ingredient, and permit flow of the compounds from a reservoir to the applicator tip.

The present invention discloses the method of inhibiting complement activation mediated by factor B inhibitors, that involves: (a) inhibiting factor B binding to properdin-bound C3b; (b) inhibiting the release of Bb; (c) inhibiting the activation of neutrophils, monocytes, platelets, and endothelium; or (d) inhibiting / reducing the formation of PC3bBb, C3a, C5a, and MAC.The present invention also discloses the novel use of factor B inhibitors in the treatment of various immunological disorders, resulting either primarily from direct immune responses such as rheumatoid arthritis, anaphylactic shock, myasthenia gravis, asthma, Alzheimer's disease, and the like, or secondarily from clinical conditions such as cardiopulmonary bypass inflammation, vascular stenosis and restenosis, burn injury, and the like.

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

The invention relates to a preparation method of a traditional Chinese medicine lotion for treating superficial wounds, and belongs to the technical field of traditional Chinese medicine preparation methods. At present, anti-infective medicines such as penicillin, sulfa, etc., are adopted to treat the superficial wounds, transformation reactions are easy to act if the penicillin is applied, and more particularly, if anaphylactic shock is not rescued in time, the life is threatening. The invention has the technical proposal that: roots of Rubus Crataegiflolius Bge, purslane, paris rhizome, fig, Cayratia japonica (Thunb.)Gagnep, sticktight, Radix Berberidis, herba andrographiis, Herba Potentilae, Herba Lobeliae Chinensis, bistort, smilax glabra, aspidium rhizome, Ampelopsis japonica, Chinese white olive, Sabia japonica, futokadsura stem, Caulis Trachelospermi, Fibraurea recisa, Common herons Bill Herb, coralbean bark, Clematis chinensis and glycyrrhiza are got; the above-mentioned medicines are put in water that is 2000ml for 30 minutes, and then are decocted under mild fire; residue is filtrated off by using gauzes to make the traditional Chinese medicine lotion for treating the superficial wounds. The preparation method has the advantage that the manufacture is simple; the made traditional Chinese medicine has small toxic and side effects, and directly reach the lesion part, and has easy absorption; the course of treatment is short, and the cure rate is high.

This invention is designed and intended to provide simple, precise delivery of a variety of medications to mucosal surfaces of a living subject, human or non-human animal, including but not limited to the nasal or rectal mucosa, which sites afford rapid absorption and therefore onset of effect of the thus delivered medication. Such medications include, but are not limited to, anticonvulsants, drugs to treat anaphylactic shock, antidotes for poisoning, and medications which are required urgently where either a parenteral formulation is not available or an i.v. route is difficult. Simplicity and needle free safety of use of the various embodiments of the invention allows its operation by laypersons, school-teachers, nurses, paramedics and non¬medical persons in e.g. the armed service. Modular embodiments of the invention facilitate mixing and matching of delivery systems with different dosages and types of medications.

Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

A carboxylic acid compound represented by formula (I): (meanings of the symbols in the formula are as mentioned in the specification) and a pharmaceutical agent comprising the compound. <>Since the compound represented by formula (I) binds to a DP receptor and shows antagonistic activity for the DP receptor, it is useful for prevention and / or treatment of diseases such as allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like. Carboxylic acid compounds represented by the following general formula (I) (wherein each symbol is as defined in the description) and drugs containing these compounds: (I) Because of binding to DP receptor and antagonizing the same, the compounds represented by the general formula (I) are useful in preventing and / or treating allergic diseases (allergic nephritis, allergic conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, etc.), systemic mast cell disease, systemic mast cell activation failure, anaphylactic shock, respiratory tract contraction, urticaria, eczema, diseases associated with itch (atopic dermatitis, urticaria, etc.), diseases (cataract, retinal detachment, inflammation, infection, sleep disorder, etc.) secondarily caused by behaviors associating itch (scratching, beating.

The invention relates to compositions suitable for plasma substitution comprising as a plasma expander a recombinant gelatin-like protein. Characteristic is that the gelatin-like protein can be a monomer or a polymer like a dimer, trimer or a tetramer of a human recombinant gelatin-like protein having an isolectric point of less than 8. The resulting gelatin-like proteins provide a method to control the clearance rate of a plasma expander by its molecular weight. Preferably the gelatin-like proteins have a low hydroxyproline content which prevents the composition from gelling and thus allows the use of high-molecular weight proteins in order to establish a suitable colloid osmotic pressure. An additional advantage of the gelatin-like proteins is that these avoid the risk of anaphylactic shock that exists in conjunction with the use of commercially available preparations.

The invention relates to a preparation method of traditional Chinese medicine for treating qi-deficiency-type ecthyma, which belongs to the technical field of traditional Chinese medicine preparation method. The existing way for treating the qi-deficiency-type ecthyma generally adopts antibiotics and sulfonamides, if penicillin is adopted, a skin test is needed before utilizing the penicillin, the penicillin is forbidden to use for positive result in the skin test, delayed anaphylactic shock can occur during the continuous application process of the penicillin for very few people to threaten the life of people when not being rescued in time. The technical scheme provided by the invention is that: Chinese dates, yams, black-bone chicken, wild cabbage, dried longan pulp, rhizoma atractylodis macrocephalae, American ginseng, lotus seeds, codonopsis pilosula, sharpleaf galangal fruits, astragalus mongholicus, rhizoma polygonati, polished round-grained rice, dry gingers, prepared rehmannia root, polygonum multiflorum, Chinese angelica, radix paeoniae alba, longan pulp, wheat, pigeonpea and liquorice are placed in the water to be soaked and to be decocted with slow fire, and the decocted liquid medicine is the traditional Chinese medicine for treating the qi-deficiency-type ecthyma. The preparation method has the advantages that the prepared traditional Chinese medicine is simple to produce, has small toxic and side effects, short course of treatment and high curative rate. Moreover, adverse reaction caused by Western medicine can also be avoided.

The invention provides an immunohistochemical SIMPLE same part marker diagnosis method and kit for a pathologic autopsy anaphylactic shock. The kit comprises a first mastocyte (MC) antibody, a first IgE antibody, a universal second antibody reagent, an antigen repair reagent, a DAB developing solution, an AEC developing solution, a buffer liquid system and the like, wherein the first antibody is a mouse-anti-human monoclonal MC antibody; and the first IgE antibody is a mouse-anti-human monoclonal IgE antibody. The kit has the characterstics of being low in price, good in specificity, high in sensitivity, high in accuracy, good in stability, simple and general. The kit is mainly applied to identification of pathology and forensic pathology; and an intuitive pathological basis for the anaphylactic shock can be accurately provided.

A method and composition for treating allergic diseases and / or airway inflammation including pollinosis, bronchial asthma, allergic rhinitis, atopic dermatitis and anaphylactic shock with the administration to a subject an amount of an anti-infectious agent such as ribavirin and optionally combined with an anti-inflammatory agent selected from inhaled steroids, leukotriene receptor antagonists and beta-2 receptor agonist.

A carboxylic acid compound represented by formula (I): (meanings of the symbols in the formula are as mentioned in the specification) and a pharmaceutical agent comprising the compound. <>Since the compound represented by formula (I) binds to a DP receptor and shows antagonistic activity for the DP receptor, it is useful for prevention and / or treatment of diseases such as allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like. Carboxylic acid compounds represented by the following general formula (I) (wherein each symbol is as defined in the description) and drugs containing these compounds: (I) Because of binding to DP receptor and antagonizing the same, the compounds represented by the general formula (I) are useful in preventing and / or treating allergic diseases (allergic nephritis, allergic conjunctivitis, atopic dermatitis, bronchial asthma, food allergy, etc.), systemic mast cell disease, systemic mast cell activation failure, anaphylactic shock, respiratory tract contraction, urticaria, eczema, diseases associated with itch (atopic dermatitis, urticaria, etc.), diseases (cataract, retinal detachment, inflammation, infection, sleep disorder, etc.) secondarily caused by behaviors associating itch (scratching, beating.

The invention relates to compositions suitable for plasma substitution comprising as a plasma expander a recombinant gelatin-like protein. Characteristic is that the gelatin-like protein essentially is free of hydroxyproline. This absence of hydroxyproline prevents the composition from gelling and thus allows the use of high-molecular weight proteins in order to establish a suitable colloid osmotic pressure. Specific advantage of the gelatin-like proteins is that these avoid the risk of anaphylactic shock that exists in conjunction with the use of commercially available preparations.

A composition includes cells of Lactobacillus paracasei MCC1849 (NITE BP-01633). The composition is in the form of a pharmaceutical composition, a food, a drink, or a feed. The pharmaceutical composition can be used for treating an inflammatory disease, ulcer, food allergies, bronchial asthma, urticaria, pollinosis, anaphylactic shock or an opportunistic infection.

The invention relates to applications of a histone deacetylase inhibitor in preparing an antishock drug, especially applications of S-(E)-3-[1-(1-benzo[d]oxazole-2-yl)-2-methylpropyl]-1H-1,2,3-triazole-4-yl]-N-Methylol acrylamide as shown in the specification in preparing the antishock drug, the shock is preferably selected from traumatic shock, hypovolemic shock, infectious shock, neurogenic shock, cardiogenic shock and anaphylactic shock, especially burning shock preferably.

The invention refers to a recombinant human diamine oxidase (DAO) with decreased glycosaminoglycan binding affinity, wherein said DAO comprises at least one amino acid modification in the glycosaminoglycan (GAG) binding domain. The present invention also refers to the use of the DAO in the treatment of a condition associated with excess histamine, specifically in the treatment of chronic allergic diseases, more specifically in the treatment of anaphylaxis, anaphylactic shock, chronic urticaria, acute urticaria, asthma, hay fever, allergic rhinitis, allergic conjunctivitis, histamine intoxication, headache, atopic dermatitis inflammatory diseases, mastocytosis, mast cell activation syndrome (MCAS), pre-eclampsia, hyperemesis gravidarum, pre-term labor, peptic ulcers, acid reflux, pruritus, and sepsis.

A method and composition for treating allergic diseases and / or airway inflammation including pollinosis, bronchial asthma, allergic rhinitis, atopic dermatitis and anaphylactic shock with the administration to a subject an amount of an anti-infectious agent such as ribavirin and optionally combined with an anti-inflammatory agent selected from inhaled steroids, leukotriene receptor antagonists and beta-2 receptor agonist.